These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 12672273)
21. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study. Sehouli J; Camara O; Schmidt M; Mahner S; Seipelt G; Otremba B; Schmalfeldt B; Tesch H; Lorenz-Schlüter C; Oskay-Ozcelik G; Cancer Chemother Pharmacol; 2009 Aug; 64(3):585-91. PubMed ID: 19156414 [TBL] [Abstract][Full Text] [Related]
22. Phase II trail of didemnin B in previously treated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group (ECOG) Study. Kucuk O; Young ML; Habermann TM; Wolf BC; Jimeno J; Cassileth PA Am J Clin Oncol; 2000 Jun; 23(3):273-7. PubMed ID: 10857892 [TBL] [Abstract][Full Text] [Related]
23. Influence of amifostine on toxicity of CHOP in elderly patients with aggressive non-Hodgkin's lymphoma--a phase II study. Späth-Schwalbe E; Lange C; Genvresse I; Krüger L; Eucker J; Schweigert M; Sezer O; Budach V; Possinger K Anticancer Drugs; 2002 Apr; 13(4):395-403. PubMed ID: 11984085 [TBL] [Abstract][Full Text] [Related]
24. Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma. Pro B; Hagemeister FB; McLaughlin P; Romaguera J; Rodriguez MA; Cabanillas F; Tiongson LP; Younes A Leuk Lymphoma; 2006 Sep; 47(9):1818-21. PubMed ID: 17064994 [TBL] [Abstract][Full Text] [Related]
25. A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma. Halm U; Etzrodt G; Schiefke I; Schmidt F; Witzigmann H; Mössner J; Berr F Ann Oncol; 2000 Jan; 11(1):113-4. PubMed ID: 10690399 [TBL] [Abstract][Full Text] [Related]
26. Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study. Ardavanis A; Mavroudis D; Kalbakis K; Malamos N; Syrigos K; Vamvakas L; Kotsakis A; Kentepozidis N; Kouroussis C; Agelaki S; Georgoulias V; Cancer Chemother Pharmacol; 2006 Dec; 58(6):742-8. PubMed ID: 16718470 [TBL] [Abstract][Full Text] [Related]
27. Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. Dummer R; Quaglino P; Becker JC; Hasan B; Karrasch M; Whittaker S; Morris S; Weichenthal M; Stadler R; Bagot M; Cozzio A; Bernengo MG; Knobler R J Clin Oncol; 2012 Nov; 30(33):4091-7. PubMed ID: 23045580 [TBL] [Abstract][Full Text] [Related]
28. Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chemotherapy: a Phase II Study of the Japanese Gynecologic Oncology Group. Katsumata N; Fujiwara Y; Kamura T; Nakanishi T; Hatae M; Aoki D; Tanaka K; Tsuda H; Kamiura S; Takehara K; Sugiyama T; Kigawa J; Fujiwara K; Ochiai K; Ishida R; Inagaki M; Noda K Jpn J Clin Oncol; 2008 Nov; 38(11):777-85. PubMed ID: 18927230 [TBL] [Abstract][Full Text] [Related]
29. Multicenter phase II study of pegylated liposomal doxorubicin in combination with vinorelbine as first-line treatment in elderly patients with metastatic breast cancer. Mlineritsch B; Schabel-Moser R; Andel J; Fridrik M; Moik M; Mayer P; Russ G; Rass C; Greil R; Onkologie; 2009 Feb; 32(1-2):18-24. PubMed ID: 19209014 [TBL] [Abstract][Full Text] [Related]
30. Pegylated liposomal doxorubicin in the CHOP regimen for older patients with aggressive (stages III/IV) non-Hodgkin's lymphoma. Tsavaris N; Kosmas C; Vadiaka M; Giannouli S; Siakantaris MP; Vassilakopoulos T; Pangalis GA Anticancer Res; 2002; 22(3):1845-8. PubMed ID: 12168880 [TBL] [Abstract][Full Text] [Related]
31. Α multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer. Xenidis N; Vardakis N; Varthalitis I; Giassas S; Kontopodis E; Ziras N; Gioulbasanis I; Samonis G; Kalbakis K; Georgoulias V Cancer Chemother Pharmacol; 2011 Jul; 68(1):63-8. PubMed ID: 20830475 [TBL] [Abstract][Full Text] [Related]
32. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity. Gómez H; Mas L; Casanova L; Pen DL; Santillana S; Valdivia S; Otero J; Rodriguez W; Carracedo C; Vallejos C J Clin Oncol; 1998 Jul; 16(7):2352-8. PubMed ID: 9667250 [TBL] [Abstract][Full Text] [Related]
33. Pegylated liposomal doxorubicin combined with trabectedin as a treatment option in uterine sarcomas: a single-institution retrospective analysis. Steinlechner M; Strobel L; Leitner K; Pan TL; Feroz B; Marth C; Zeimet AG Int J Gynecol Cancer; 2024 Aug; 34(8):1196-1202. PubMed ID: 38688662 [TBL] [Abstract][Full Text] [Related]
34. Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer. Kim KH; Jelovac D; Armstrong DK; Schwartz B; Weil SC; Schweizer C; Alvarez RD Gynecol Oncol; 2016 Feb; 140(2):210-4. PubMed ID: 26644263 [TBL] [Abstract][Full Text] [Related]
35. High dose cyclophosphamide plus recombinant human granulocyte-colony stimulating factor (rhG-CSF) in the treatment of follicular, low grade non-Hodgkin's lymphoma: CALGB 9150. Lichtman SM; Petroni G; Schilsky RL; Johnson JL; Perri RT; Niedzwiecki D; Sklar J; Barcos M; Peterson BA Leuk Lymphoma; 2001; 42(6):1255-64. PubMed ID: 11911406 [TBL] [Abstract][Full Text] [Related]
36. Pegylated liposomal doxorubicin with vinorelbine in metastatic breast carcinoma. A phase I-II clinical investigation. Gebbia V; Mauceri G; Fallica G; Borsellino N; Tirrito ML; Testa A; Varvara F; Colombo A; Ferrera P Oncology; 2002; 63(1):23-30. PubMed ID: 12187067 [TBL] [Abstract][Full Text] [Related]
37. Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO. Oskay-Oezcelik G; Koensgen D; Hindenburg HJ; Klare P; Schmalfeldt B; Lichtenegger W; Chekerov R; Al-Batran SE; Neumann U; Sehouli J; Anticancer Res; 2008; 28(2B):1329-34. PubMed ID: 18505074 [TBL] [Abstract][Full Text] [Related]
38. A third generation regimen VACOP-B with or without adjuvant radiotherapy for aggressive localized non-Hodgkin's lymphoma: report from the Italian Non-Hodgkin's Lymphoma Co-operative Study Group. Santini G; De Souza C; Aversa S; Patti C; Tedeschi L; Candela M; Olivieri A; Chisesi T; Rubagotti A; Centurioni R; Nardi V; Congiu M; Gennaro M; Truini M; Braz J Med Biol Res; 2004 May; 37(5):719-28. PubMed ID: 15107935 [TBL] [Abstract][Full Text] [Related]
39. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma. Stoppa AM; Bouabdallah R; Chabannon C; Novakovitch G; Vey N; Camerlo J; Blaise D; Xerri L; Resbeut M; Di Stefano D; Bardou VJ; Gastaut JA; Maraninchi D J Clin Oncol; 1997 May; 15(5):1722-9. PubMed ID: 9164178 [TBL] [Abstract][Full Text] [Related]
40. Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study. Hochster HS; Kim KM; Green MD; Mann RB; Neiman RS; Oken MM; Cassileth PA; Stott P; Ritch P; O'Connell MJ J Clin Oncol; 1992 Jan; 10(1):28-32. PubMed ID: 1727921 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]